Beximco Pharmaceuticals Limited

Beximco Pharmaceuticals Limited (DSE: BXPHARMA, CSE: BXPH, LSE: BXP) manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients (API) and intravenous (IV) fluids. The company’s product portfolio includes a variety of therapeutic areas, such as analgesics, antibiotics, cardiovascular, central nervous system, dermatology, gastroenterology and respiratory. It also has contract manufacturing agreements with global pharmaceutical firms. The company is present in 45 countries and is the largest exporter of pharmaceuticals in Bangladesh.

The objective of Beximco Pharmaceuticals Limited’s Investor Relations is to ensure continuous and open communication with all financial market participants.

• Stock Info on DSE » Stock Info at CSE » Stock Info at LSE »

• FY 2012
• FY 2011
• FY 2010
• FY 2009
• FY 2008

Financial Results and Presentations

Q1 FY2012 Financial Results

 

Corporate Governance and Other

Advisors

Articles of Association

Corporate Governance

Key Company Information

Placing and Admission of GDRs to AIM

Rights of Shareholders

Share Information

Transfer Restrictions

Financial Results and Presentations

Q2 FY2011 Financial Results

Q1 FY2011 Financial Results

 

Press Releases

Q2 FY2011 Earning Release

Issued Stock Dividend (7-Jul-11)

AGM Statement (4-Jul-11)

Amalgamation of Bextex (12 July 2011)

Q1 FY2011 Earning Release

Directorate Change (12-Jan-11)

 

Financial Calendar

Annual General Meeting

 

Corporate Governance and Other

Advisors

Articles of Association

Corporate Governance

Key Company Information

Placing and Admission of GDRs to AIM

Rights of Shareholders

Share Information

Transfer Restrictions

Annual Report

FY2010 Annual Report

 

Financial Results and Presentations

Full Year FY2010 Financial Results

Q3 FY2010 Financial Results

Q2 FY2010 Financial Results

Q1 FY2010 Financial Results

 

Press Releases

Full Year FY2010 Earning Release

GDR Programme Change (25-Nov-10)

Q3 FY2010 Earning Release

Q2 FY2010 Earning Release

Stock Dividend Issued (23-Jun-10)

AGM Statement (15-Jun-10)

Q1 FY2010 Earning Release

Preference Share Conversion (4-May-10)

Price Sensitive Information (29-Apr-10)

Preference Share Conversion (1-Feb-10)

Completion of Preference Share Placing (11-Jan-10)

Annual Report

FY2009 Annual Report

 

Financial Results and Presentations

Full Year FY2009 Financial Results

Q3 FY2009 Financial Results

Q2 FY2009 Financial Results

 

Press Releases

Full Year FY2009 Earning Release

Approves Issuance of Preference Shares (22-Oct-09)

Clarification Re Preference Shares Issue (19-Oct-09)

Announces Extra Ordinary General Meeting (10-Sep-09)

Announces Issuance of Preference Shares (3-Sep-09)

Q2 FY2009 Earning Release

Annual General Meeting Statement (18-Jun-09)

Exports Oseltamivir Capsules to America (20-May-09)

Notice of Annual General Meeting (14-May-09)

Price Sensitive Information (30-Apr-09)

Extra Ordinary General Meeting (19-Feb-09)

Private Placement of Shares (27-Jan-09)

Price Sensitive Information (26-Jan-09)

Annual Report

FY2008 Annual Report

 

Financial Results and Presentations

Q2 FY2008 Financial Results

 

Press Releases

Full Year FY2008 Earning Release

Export Approval to Gulf Countries (14-Nov-08)

Commences Exports to Chile (9-Sep-08)

GMP Clearance from TGA Australia (22-Jul-08)

Notice of Annual General Meeting (6-May-08)

Technology Agreement with Roche (9-Jan-08)